Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $39.00.

A number of brokerages have commented on ARTV. Wedbush lifted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Needham & Company LLC lifted their price target on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Cantor Fitzgerald lifted their price target on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $7.87 on Friday. The business’s 50 day simple moving average is $8.41 and its two-hundred day simple moving average is $5.72. The stock has a market capitalization of $194.55 million, a P/E ratio of -2.22 and a beta of 2.86. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Sell-side analysts expect that Artiva Biotherapeutics will post -2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, COO Jennifer Bush sold 8,790 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $79,197.90. Following the completion of the transaction, the chief operating officer owned 337,920 shares of the company’s stock, valued at $3,044,659.20. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Subhashis Banerjee sold 7,037 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $63,403.37. Following the transaction, the insider directly owned 144,963 shares of the company’s stock, valued at $1,306,116.63. The trade was a 4.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 53,040 shares of company stock worth $477,890 over the last three months. 21.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics during the 3rd quarter valued at approximately $41,000. Dimensional Fund Advisors LP bought a new position in Artiva Biotherapeutics during the 1st quarter valued at approximately $131,000. OMERS ADMINISTRATION Corp bought a new position in Artiva Biotherapeutics during the 4th quarter valued at approximately $91,000. Finally, Sanctuary Advisors LLC bought a new position in Artiva Biotherapeutics during the 1st quarter valued at approximately $139,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.